HIT TO LEAD CHEMISTRY UNDER PERFORMANCE AREA 2 OF ID/IQ CONTRACT NO. HHSN271201800001I

这项研究是NIH帮助结束成瘾长期(Hear)倡议的一部分，该倡议旨在加快科学解决方案，以了解疼痛的基础并加强临床疼痛管理。 任务订单编号75N95022F00007倾斜的Grace(德克萨斯大学MD Anderson 癌症中心)-MCSP-HIT领导化学(任务订单)现授予库里亚 Global，Inc.(承包商)，ID/IQ合同HHSN271201800001I(父合同)。 开展构效关系(SAR)分析与设计、合成、体外吸收 分布、新陈代谢、排泄和毒理学(ADMET)、计算化学/计算机辅助 药物发现(CADD)以及储存和运输的复合物流，以支持贡献者 GRACE(德克萨斯大学MD Anderson癌症中心)开发一种新的治疗癌症的有效方法 治疗疼痛。这将通过提高他们的小分子前体药物的SAR/SPR来实现 启动小分子利用它们的分析和体外ADMET来识别新的前药。

This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. Task Order Number 75N95022F00007 tilted Grace (University of Texas MD Anderson Cancer Center) – MCSP – Hit to Lead Chemistry (Task Order)) is hereby awarded to Curia Global, Inc. (Contractor) under ID/IQ Contract HHSN271201800001I (Parent Contract). to develop structure activity relationship (SAR) analysis and design, synthesis, in vitro absorption, distribution, metabolism, excretion and toxicology (ADMET), computational chemistry/Computer Aided Drug Discovery (CADD), and compound logistics of storage and shipping to support the Contributor Grace (University of Texas MD Anderson Cancer Center) in developing a novel therapeutic effective in treating pain. This will be achieved by advancing the SAR/SPR of their small molecule prodrugs of starting small molecules utilizing their assays and in vitro ADMET to identify novel, prodrugs.